Cytori Cell Research Institute,Inc. Logo

Cytori Cell Research Institute,Inc.

Develops devices and cell therapies using a patient's fat tissue to repair injury and treat disease.

3750 | T

Overview

Corporate Details

ISIN(s):
JP3426500009
LEI:
Country:
Japan
Address:
千代田区麹町2丁目3番3号
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Cytori Cell Research Institute, Inc., now operating as ADR120S, Inc., is a regenerative medicine company focused on developing novel cell therapies. The company engages in the research, development, production, and sale of medical devices and related kits for cell-based treatments. Its core technology centers on a proprietary system to extract and concentrate adipose-derived regenerative cells (ADRCs) from a patient's own fat tissue. These therapies are designed to repair injured tissue, preserve function, and address various diseases with unmet medical needs, such as osteoarthritis and diabetic foot lesions. The company aims to provide safe and effective treatment options by harnessing the potential of cellular therapy.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-14 08:04
Registration Form
確認書
Japanese 8.6 KB
2025-11-14 08:03
Interim / Quarterly Report
半期報告書-第22期(2025/04/01-2026/03/31)
Japanese 194.2 KB
2025-11-07 07:42
Registration Form
確認書
Japanese 8.3 KB
2025-11-07 07:39
Annual Report
訂正有価証券報告書-第21期(2024/04/01-2025/03/31)
Japanese 597.9 KB
2025-07-01 04:31
AGM Information
臨時報告書
Japanese 24.3 KB
2025-06-27 09:17
Registration Form
確認書
Japanese 8.2 KB
2025-06-27 09:16
Annual Report
有価証券報告書-第21期(2024/04/01-2025/03/31)
Japanese 946.5 KB
2025-06-27 09:16
Governance Information
内部統制報告書-第21期(2024/04/01-2025/03/31)
Japanese 23.7 KB
2025-05-30 02:01
Regulatory Filings
臨時報告書
Japanese 20.1 KB
2025-02-10 08:41
AGM Information
臨時報告書
Japanese 20.5 KB
2025-01-06 08:19
Regulatory Filings
臨時報告書
Japanese 19.0 KB
2024-11-14 08:06
Report Publication Announcement
確認書
Japanese 8.1 KB
2024-11-14 08:05
Interim / Quarterly Report
半期報告書-第21期(2024/04/01-2025/03/31)
Japanese 190.1 KB
2024-09-24 09:07
M&A Activity
臨時報告書
Japanese 19.8 KB
2024-07-29 08:30
Major Shareholding Notification
臨時報告書
Japanese 21.5 KB

Automate Your Workflow. Get a real-time feed of all Cytori Cell Research Institute,Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Cytori Cell Research Institute,Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Cytori Cell Research Institute,Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

HANDOK Inc. Logo
South Korea
002390
Hanmi Pharm. Co., Ltd. Logo
Biopharma firm developing innovative diabetes and cancer drugs for patients and professionals.
South Korea
128940
Hanmi Science Co.,Ltd Logo
A holding company managing R&D-focused pharmaceutical, API, and medical device firms.
South Korea
008930
Hansa Biopharma Logo
Develops antibody-cleaving enzymes to treat rare diseases and enable organ transplants.
Sweden
HNSA
Harmony Biosciences Holdings, Inc. Logo
Develops innovative therapies for rare neurological diseases, focusing on conditions like narcolepsy.
United States of America
HRMY
HARROW, INC. Logo
Develops branded ophthalmic therapies and custom compounded solutions for North American eyecare.
United States of America
HROW
HCW Biologics Inc. Logo
Developing novel immunotherapies to treat aging-related chronic inflammation.
United States of America
HCWB
Heidelberg Pharma AG Logo
Develops cancer therapies using its proprietary ATAC Antibody-Drug Conjugate technology.
Germany
HPHA
Helixmith Co., Ltd Logo
South Korea
084990
HEMOGENYX PHARMACEUTICALS PLC Logo
Develops CAR-T therapies for blood cancers, autoimmune disorders, and viral infections.
United Kingdom
HEMO

Talk to a Data Expert

Have a question? We'll get back to you promptly.